The first delivery of Integrum prosthetic components to Ottobock has been carried out in the United States. This marks the start of Integrum’s collaboration with Ottobock Healthcare. The order represents a strategically important milestone since Ottobock can start to sell & market Integrum’s products on the US market. “We are very proud to collaborate with […]
read moreNasdaq (Nasdaq: NDAQ) announces that the trading in Integrum AB’s shares (short name: INTEG B) commenced today on Nasdaq First North in Stockholm. Please read more here
read moreIntegrum collaborators have been awarded for outstanding record of innovative achievement in the field of prosthetics and/or orthotics. The Blatchford Award 2017 has been presented to the multidisciplinary team of surgeons, physiotherapists, occupational therapists, and prosthetists from Sahlgrenska University Hospital (SUH), as well as researchers from Chalmers University of Technology (CTH) and University of Gothenburg […]
read moreIntegrum has talking the steps to be a listed company on Nasdaq First North. We have reached several milestones in the listing process and the date is set to be May 15 as the introduction date. This will enable several advantages for Integrum and we will be able to provide additional resources for development, marketing […]
read moreIntegrum has entered a collaboration with Ottobock in the field of osseointegration regarding distribution of prosthetic connection elements related to Integrum’s OPRA implant system. Integrum is thrilled to collaborate with Ottobock, the market leader in prosthetics, to distribute Integrum’s prosthetic components in the US. This is a major step forward in developing Integrums presence in […]
read moreThe University of California San Francisco (UCSF) and the Orthopaedic Surgical Osseointegration Society (OSOS) are arranging the 7th international conference about Advances in Orthopaedic Osseointegration. Several Integrum co-workers will participate and share some of our latest developments. Integrum will arrange a surgical course at the conference. Please read more here
read moreIntegrum is introducing the OPRA Implant System Platform G to be used for transfemoral patients. The new platform is CE labeled and approved by the FDA and will be available in January 2017. The OPRA Implant System Platform G improves the mechanical performance of the system, simplifies the surgical procedure and enhances osseointegration. Please contact […]
read moreNeuromotus is a revolutionizing technology to relieve Phantom Limb Pain. The technology has been proven in a clinical trial with good results. The results have recently been published in the medical journal The Lancet. The technology is in the final stage of development. Please read more at our new product website Neuromotus.se and sign up […]
read moreUCSF Medical Center is planning to treat several Transfemural (above the knee) patients on a yearly basis. Apart from hospital expenses, patients traveling from across the nation will have to find resources to cover the cost of lodging and travel in order to have the first clinical screening, as well as surgery and aftercare. UCSF […]
read more